Defibrotide is equipotent to urokinase in stimulating arterial and venous thrombolysis.
The action of iv. defibrotide (100 mg/kg bolus injection, followed by 30 mg/kg x h) on arterial and venous thrombus formation was studied in rabbits and compared with iv. urokinase (4,000 IU/kg bolus injection, followed by 1,500 IU/kg x h). In comparison with saline treated controls, defibrotide reduced the thrombus weight by 43% in veins and 76% in arteries (P less than 0.01), while urokinase reduced the thrombus weight by 50% in veins and 71% in arteries. The data suggest a potent thrombolytic activity of defibrotide which is comparable to that of urokinase.
Grodzińska
L
L
Institute of Pharmacology, N. Copernicus Medical Academy, Cracow, Poland.
König
E
E
Schrör
K
K
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D008297:Male; D011089:Polydeoxyribonucleotides / Q000494:pharmacology*; D011817:Rabbits; D013927:Thrombosis / Q000473:pathology / Q000517:prevention & control; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology*
D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C036901:defibrotide; D014568:Urokinase-Type Plasminogen Activator